Previous researches demonstrated that the CEA and CA15-3 levels are associated with tumor burden indicators including tumor size and lymph node status[17, 20] and patients with locally advanced breast cancer exhibit significantly higher levels of CEA and CA 15–3[21, 22]. This evidence concerns the gene CEACAM5 and breast cancer.